Ziyi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ziyi Wang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chengkang Wang
Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang city, People’s Republic of China
2 shared publications - Xiaoxuan Song
Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang city, People’s Republic of China
2 shared publications - Yingshi Zhang
Shenyang Pharmaceutical University
2 shared publications - Kaisi Yang
Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang city, People’s Republic of China
1 shared publication - Lei Han
Department of Hepatobiliary Surgery, General Hospital of Northern Theater Command, Shenyang City, People’s Republic of China
1 shared publication - Mingyang Mao
Department of Pharmacy, Wannan Medical University Affiliated Tongling People’s Hospital, tongling City, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 15 September 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
Novel drug target ADAM8/17 is associated with the occurrence of intrahepatic cholangiocarcinoma via Notch1/Integrinα5 pathway
- 15 September 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
Open AccessNovel drug target ADAM8/17 is associated with the occurrence of intrahepatic cholangiocarcinoma via Notch1/Integrinα5 pathway
- Open Access
- 9 December 2025
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
The role of ADAM8 in intrahepatic cholangiocarcinoma
Currently, there are no approved first-line targeted inhibitors for ICC. ADAM8 is one of the most frequently over-expressed proteins in human intrahepatic cholangiocarcinoma (ICC). This review examines the potential of ADAM8 as a direct therapeutic target for ICC, emphasizing its downstream impact on Notch and Integrin signaling pathways. Collectively, these findings suggest ADAM8 may represent a novel strategy for ICC management. We have consolidated pre-clinical research on ADAM8 inhibitors, which demonstrate inhibitory effects on epithelial mesenchymal transition (EMT) and tumor angiogenesis by cleaving substrates such as CHL1 and CD23 to form their active fragments. And its substrate form may be monomers, dimers, or even polymers. This review provides a critical discussion of the therapeutic potential of ADAM8 inhibitors in ICC. However, further challenges remain, including enhancing inhibitor specificity, conducting long-term studies to thoroughly evaluate the benefits and risks associated with targeting ADAM8.
- 9 December 2025
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessThe role of ADAM8 in intrahepatic cholangiocarcinoma
Currently, there are no approved first-line targeted inhibitors for ICC. ADAM8 is one of the most frequently over-expressed proteins in human intrahepatic cholangiocarcinoma (ICC). This review examines the potential of ADAM8 as a direct therapeutic target for ICC, emphasizing its downstream impact on Notch and Integrin signaling pathways. Collectively, these findings suggest ADAM8 may represent a novel strategy for ICC management. We have consolidated pre-clinical research on ADAM8 inhibitors, which demonstrate inhibitory effects on epithelial mesenchymal transition (EMT) and tumor angiogenesis by cleaving substrates such as CHL1 and CD23 to form their active fragments. And its substrate form may be monomers, dimers, or even polymers. This review provides a critical discussion of the therapeutic potential of ADAM8 inhibitors in ICC. However, further challenges remain, including enhancing inhibitor specificity, conducting long-term studies to thoroughly evaluate the benefits and risks associated with targeting ADAM8.